keyword
Keywords -childhood cancer survivor coh...

-childhood cancer survivor cohort late effect

https://read.qxmd.com/read/37151105/effect-of-12-months-testosterone-replacement-therapy-on-bone-mineral-density-and-markers-of-bone-turnover-in-testicular-cancer-survivors-results-from-a-randomized-double-blind-trial
#21
RANDOMIZED CONTROLLED TRIAL
P L Jørgensen, M Kreiberg, N Jørgensen, A Juul, P S Oturai, C Dehlendorff, J Lauritsen, T Wagner, J Rosenvilde, G Daugaard, C R Medici, N R Jørgensen, M Bandak
BACKGROUND: Testicular cancer survivors (TCS) are at risk of Leydig cell insufficiency, which is a condition characterized by elevated luteinising hormone (LH) in combination with low levels of testosterone. It has been suggested that this condition is associated with impaired metabolic profile and low bone mineral density (BMD). The primary aim of the randomized double-blind trial NCT02991209 was to evaluate metabolic profile after 12-months testosterone replacement therapy (TRT) in TCS with mild Leydig cell insufficiency...
July 2023: Acta Oncologica
https://read.qxmd.com/read/37119033/reproduction-patterns-among-classical-hodgkin-lymphoma-survivors-treated-with-beacopp-and-abvd-in-sweden-denmark-and-norway-a-population-based-matched-cohort-study
#22
JOURNAL ARTICLE
Joshua P Entrop, Caroline E Weibull, Karin E Smedby, Lasse H Jakobsen, Andreas K Øvlisen, Daniel Molin, Ingrid Glimelius, Anna Marklund, Harald Holte, Alexander Fosså, Knut B Smeland, Tarec C El-Galaly, Sandra Eloranta
Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18-40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995-2018, who were linked to national medical birth registers...
August 15, 2023: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/36952136/under-recognition-and-treatment-of-lymphedema-in-head-and-neck-cancer-survivors-a-database-study
#23
JOURNAL ARTICLE
Michael D Stubblefield, Derek Weycker
PURPOSE: Head and neck cancer (HNC) will be diagnosed in approximately 54,000 Americans in 2022 with more than 11,000 dying as a result. The treatment of HNC often involves aggressive multimodal therapy including surgery, radiotherapy, and systemic therapy. HNC and its treatments are associated with multiple painful and function-limiting neuromusculoskeletal and visceral long-term and late effects. Among these is head and neck lymphedema (HNL), the abnormal accumulation of protein rich fluid, in as many as 90% of survivors...
March 23, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/36929478/chronic-health-conditions-among-long-term-survivors-of-adolescent-and-young-adult-aya-cancer-a-comparison-of-outcomes-in-israel-and-the-united-states
#24
JOURNAL ARTICLE
Samah Hayek, Gilad Libresco, Noam Barda, Chun Chao, Lanfang Xu, Kimberly L Cannavale, Shai Izraeli, Saro H Armenian
BACKGROUND: There is a paucity of information on health outcomes of adolescent and young adult (AYA) cancer survivors living outside North America and Europe. This study compared outcomes in AYA cancer survivors in Israel with individuals without cancer and similar demographics and access to health care, and to AYA cancer survivors living in the United States. METHODS: This study included 12,674 2-year survivors of AYA (aged 15-39 years) cancer diagnosed between 2000 and 2018 at Clalit Health Services (CHS) in Israel...
March 17, 2023: Cancer
https://read.qxmd.com/read/36868138/breast-cancer-breast-cancer-directed-radiation-therapy-and-risk-of-hypothyroidism-a-systematic-review-and-meta-analysis
#25
REVIEW
Elisabeth Solmunde, Anne Mette Falstie-Jensen, Ebbe L Lorenzen, Marianne Ewertz, Kristin V Reinertsen, Olaf M Dekkers, Deirdre P Cronin-Fenton
OBJECTIVE: Breast cancer and breast cancer-directed radiation therapy (RT) may increase the risk of late effects, such as hypothyroidism. We conducted a systematic review and meta-analysis to investigate the association between breast cancer, RT, and risk of hypothyroidism in breast cancer survivors. METHODS: Through February 2022, we searched PubMed, EMBASE, and references of relevant articles, to identify papers on breast cancer and breast cancer-directed RT and subsequent risk of hypothyroidism...
April 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/36758375/spectrum-of-second-primary-malignancies-and-cause-specific-mortality-in-pediatric-and-adult-langerhans-cell-histiocytosis
#26
JOURNAL ARTICLE
Gaurav Goyal, Richa Parikh, Joshua Richman, Jithma P Abeykoon, Diana Morlote, Ronald S Go, Smita Bhatia
With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a growing survivor population that might be at risk for late mortality from non-LCH causes, including second primary malignancies (SPMs). We undertook a large study using the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the patterns of SPMs and cause-specific mortality among individuals with LCH (2000-2016) from the US. We found an increased risk of SPMs in the cohort (standardized incidence ratio [SIR] 2...
February 6, 2023: Leukemia Research
https://read.qxmd.com/read/36715320/chronic-fatigue-in-long-term-survivors-of-hodgkin-s-lymphoma-after-contemporary-risk-adapted-treatment
#27
JOURNAL ARTICLE
Siri A Eikeland, Knut B Smeland, Victoria Charlotte Simensen, Unn-Merete Fagerli, Hanne S Bersvendsen, Cecilie E Kiserud, Alexander Fosså
BACKGROUND: Chronic fatigue (CF), substantial fatigue for ≥ six months, can manifest as a late effect (LE) after cancer treatment, and may affect several aspects of life. In a Norwegian cohort of Hodgkin's lymphoma survivors (HLS), more than a decade after contemporary risk-adapted treatment regimens with limited use of radiotherapy (RT), we assessed: (1) Prevalence of, (2) factors associated with (3) and implications of CF on socioeconomic status (SES) and work ability (WA)...
January 30, 2023: Acta Oncologica
https://read.qxmd.com/read/36585575/quality-of-life-of-patients-with-rare-cancer-a-comparison-with-patients-with-colorectal-cancer-and-the-association-with-disease-trajectory-related-factors
#28
JOURNAL ARTICLE
Esmee Driehuis, Eline de Heus, Marga Schrieks, Vivian Engelen, Tineke E Buffart, Geraldine R Vink, Saskia F A Duijts
PURPOSE: Differences in quality of life (QoL) between patients with rare and common cancer might be explained by the specific challenges patients with rare cancer face during their disease trajectory, but research is scarce. This study aimed to (1) assess the difference in QoL between patients with rare and common cancer (i.e. colorectal cancer (CRC)) and (2) examine the association between disease trajectory-related factors and QoL in patients with rare cancer. METHODS: Cross-sectional data were collected among adults with rare cancer by a nationwide online survey in the Netherlands...
December 31, 2022: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/36582267/patient-reported-outcomes-paternity-relationship-and-fertility-in-testicular-cancer-survivors-results-from-a-prospective-observational-single-institution-trial
#29
JOURNAL ARTICLE
Davide Bimbatti, Eleonora Lai, Francesco Pierantoni, Marco Maruzzo, Aichi Msaki, Chiara De Toni, Michele Dionese, Alessandra Feltrin, Umberto Basso, Vittorina Zagonel
PURPOSE: Testicular cancer (TC) is the most common solid tumor in young adults. 95% of patients are cured, but they may experience late adverse effects (anxiety, fear of recurrence, and sexual dysfunction) with an impact on daily life. We attempted to assess Patient Reported Outcomes (PROMs), long-term sexual disorders, and difficulties in achieving fatherhood in a cohort of TC survivors, as well as their possible correlation with previous cancer treatments. METHODS: Different questionnaires, such as the Impact of Cancer (IOC) and the Body Image Scale (BIS), were used to investigate the distinct areas of the PROMs...
2022: Patient Preference and Adherence
https://read.qxmd.com/read/36498489/pre-diagnosis-sleep-status-and-survival-after-a-diagnosis-of-ovarian-cancer-a-prospective-cohort-study
#30
JOURNAL ARTICLE
Xiaoying Li, Chang Gao, Yifan Wei, Zhaoyan Wen, Xinyu Li, Fanghua Liu, Tingting Gong, Shi Yan, Xue Qin, Song Gao, Yuhong Zhao, Qijun Wu
Objective: To explore if pre-diagnosis sleep status is associated with overall survival (OS) of ovarian cancer (OC). Methods: This is a prospective cohort study of 853 OC patients newly diagnosed between 2015 and 2020. Sleep status was measured by the Pittsburgh Sleep Quality Index (PSQI). Vital status of patients was obtained through active follow-up and linkage to medical records and cancer registry. The Cox proportional hazards regression model was utilized to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for aforementioned associations...
November 23, 2022: Journal of Clinical Medicine
https://read.qxmd.com/read/36289184/the-effect-of-changing-pregnancy-intentions-on-preconception-health-behaviors-a-prospective-cohort-study
#31
JOURNAL ARTICLE
Hena Naz Din, David Strong, Savitri Singh-Carlson, Heather L Corliss, Sheri J Hartman, Hala Madanat, H Irene Su
PURPOSE: Pregnancy intentions are associated with preconception health behaviors but are understudied among female adolescent and young adult (AYA) cancer survivors. Preconception health is critical for survivors because they face unique risks to fertility and pregnancy from late effects of cancer treatments. This study prospectively assessed the effect of pregnancy intention on physical activity (PA) and smoking behaviors among female AYA survivors. METHODS: A cohort of 1049 female AYA survivors were recruited between 2013 and 2017...
October 27, 2022: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/36250317/late-toxicity-comparison-of-alkylating-based-maintenance-regimen-with-cyclophosphamide-vac-vs-ifosfamide-vai-in-ewing-sarcoma-survivors-treated-in-the-randomized-clinical-trial-euro-ewing99-r1-in-france
#32
RANDOMIZED CONTROLLED TRIAL
Victoria Corvest, Perrine Marec-Bérard, Cyril Lervat, Hélène Pacquement, Maud Toulmonde, Jean-Claude Gentet, Valérie Laurence, Morgane Cleirec, Ludovic Mansuy, Emmanuelle Bompas, Marie-Pierre Castex, Sophie Taque, Bruno Filhon, Marie-Dominique Tabone, Cécile Verité, Natacha Entz-Werle, Laure Saumet, Gregory Guimard, Morgane Pondrom, Christine Chevreau, Jennifer Flandrin, Lise Duranteau, Christine Rousset-Jablonski, Laurence Brugières, Marta Jimenez, Marie-Cécile Le Deley, Nathalie Gaspar, Brice Fresneau
In Euro-EWING99-R1 randomized trial, cyclophosphamide was shown to be noninferior to ifosfamide in the consolidation of standard-risk Ewing sarcoma (SR-EWS) after a common induction with VIDE (vincristine-ifosfamide-doxorubicin-etoposide). We present the results of the late effects analysis of VAC (vincristine-dactinomycin-cyclophoshamide) vs VAI (vincristine-dactinomycin-ifosfamide) conducted in Euro-EWING99-R1 French cohort. Of 267 French randomized patients, 204 were alive and free-of-relapse at 5-years including 172 with available long-term follow-up data concerning cardiac, renal and/or gonadal functions (sex-ratio M/F = 1...
April 15, 2023: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/36174935/linking-the-center-for-international-blood-and-marrow-transplant-research-cibmtr-registry-to-the-california-cancer-registry-and-california-hospital-patient-discharge-data
#33
JOURNAL ARTICLE
Theresa H M Keegan, Ann Brunson, Julianne J P Cooley, Sara J Schonfeld, Christa L Meyer, Bryan Valcarcel, Renata Abrahao, Ted Wun, Jeffery Auletta, Lori Muffly, Lindsay M Morton
BACKGROUND: Advances in hematopoietic cell transplant (HCT) have substantially improved patient survival, increasing the importance of studying outcomes and long-term adverse effects in the rapidly growing population of HCT survivors. Large-scale registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR) are a valuable resource for studying mortality and late effects after HCT, with detailed data reported by HCT centers on transplant-related factors and key outcomes...
September 27, 2022: Transplantation and cellular therapy
https://read.qxmd.com/read/36048313/incidence-and-predictors-of-recurrent-sick-leave-in-survivors-who-returned-to-work-after-allogeneic-hematopoietic-cell-transplantation
#34
JOURNAL ARTICLE
Saiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori, Tomoko Matsuura, Masayoshi Masuko, Makoto Murata, Haruko Tashiro, Shinichi Kako, Atsushi Satake, Maki Hagihara, Shuichi Ota, Takeshi Saito, Kumiko Kagawa, Yayoi Matsuo, Hidehiro Itonaga, Nobuhiko Uoshima, Hiroki Yamaguchi, Kensuke Naito, Miyako Takahashi, Takahiro Fukuda
BACKGROUND: Although rather favorable probabilities of return to work have been reported after allogeneic hematopoietic cell transplantation (allo-HCT), survivors often have difficulty continuing to work because of their immunocompromised status and diverse late effects after allo-HCT. We evaluated the incidence of and risk factors for recurrent sick leave in allo-HCT survivors after they initially returned to work. METHODS: We targeted allo-HCT survivors who were employed at diagnosis, aged 20-64 at survey, and survived for ≥ 2 years without relapse...
September 1, 2022: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/35971100/long-term-follow-up-on-hiv-infected-and-non-infected-women-with-cervical-cancer-from-tanzania-staging-access-to-cancer-directed-therapies-and-associated-survival-in-a-real-life-remote-setting
#35
JOURNAL ARTICLE
Laura Glasmeyer, Ruby Doryn Mcharo, Liset Torres, Tessa Lennemann, Elizabeth Danstan, Nice Mwinuka, Mona Judick, William Mueller, Wilbert Mbuya, Michael Hölscher, Ralph Lellé, Christof Geldmacher, Arne Kroidl, John Rwegoshora France
BACKGROUND: Worldwide 85% of cervical cancer (CC) related deaths occur in low- and middle-income countries. Sub-Saharan Africa is burdend by an overlapping high incidence of CC as well as HIV infection, a risk factor for HPV associated disease progression. Recent upscaling of CC screening activities increased the number of CC diagnoses in a previous unscreened population. The aim of the 2H study was to follow up on women with CC in the context of available health care services in Tanzania in relation to their HIV infection status...
August 15, 2022: BMC Cancer
https://read.qxmd.com/read/35946782/medication-burden-among-pediatric-cancer-survivors-analysis-of-a-population-wide-electronic-database-in-hong-kong
#36
JOURNAL ARTICLE
Celeste Lom-Ying Ewig, Ka Ho Hui, Samantha Lai Ka Lee, Alex Wing Kwan Leung, Grace Lai-Hung Wong, Chi Kong Li, Yin Ting Cheung
BACKGROUND: Few studies have evaluated the medication burden borne by survivors of pediatric cancer. This study aimed to describe the drug utilization pattern of chronic medications in a cohort of young pediatric cancer survivors. METHODS: This was a population-based study of patients diagnosed with cancer at aged ≤18 years between 2000 and 2013 in Hong Kong, and had survived ≥5 years post-diagnosis. The primary outcome is the use of any chronic medication (medications that were prescribed for ≥30 consecutive days within a 6-month period)...
August 10, 2022: JNCI Cancer Spectrum
https://read.qxmd.com/read/35931832/sexual-health-and-wellbeing-among-female-pelvic-cancer-survivors-following-individualized-interventions-in-a-nurse-led-clinic
#37
JOURNAL ARTICLE
Linda Åkeflo, Gail Dunberger, Eva Elmerstig, Viktor Skokic, Gunnar Steineck, Karin Bergmark
PURPOSE: Treatment-induced sexual and intestinal dysfunctions coexist among women after pelvic radiotherapy. We aimed to explore if sexual health and wellbeing may be improved after radiotherapy following nurse-led interventions and if an association exists between improved intestinal health and sexual health. METHODS: A population-based cohort of women treated with pelvic radiotherapy underwent interventions at a nurse-led clinic at Sahlgrenska University Hospital, Sweden, from 2011 to 2017...
August 5, 2022: Supportive Care in Cancer
https://read.qxmd.com/read/35857866/long-term-follow-up-and-health-related-quality-of-life-among-cancer-survivors-with-stage-iea-orbital-type-lymphoma-after-external-photon-beam-radiotherapy-results-from-a-longitudinal-study
#38
JOURNAL ARTICLE
Christian Hoffmann, Philipp Rating, Nikolaos Bechrakis, Anja Eckstein, Ekaterina Sokolenko, Leyla Jabbarli, Henrike Westekemper, Christopher Mohr, Claus Schmeling, Andreas Huettmann, Julia von Tresckow, Sophia Göricke, Cornelius Deuschl, Patricia Johansson, Christoph Poettgen, Thomas Gauler, Nika Guberina, Sourour Moliavi, Martin Stuschke, Maja Guberina
We assessed the long-term outcomes and treatment-related adverse effects of patients with Stage I, "orbital-type" lymphomas that were uniformly treated with photons. All consecutive patients diagnosed with low-grade, Ann Arbor Stage IEA orbital lymphoma treated between 1999 and 2020 at our department were retrospectively reviewed. We excluded patients with exclusive conjunctival involvement, typically treated with en face electrons. In order to quantify radiotherapy related side effects we applied the CTCAE criteria, analyzed changes in visual acuity, quantified dry eye symptoms by use of the Ocular Surface Disease Index (OSDI) score and applied the EORTC QLQ-C30 questionnaire for quality of life (QoL) assessment...
July 20, 2022: Hematological Oncology
https://read.qxmd.com/read/35841204/kidney-disease-in-very-long-term-survivors-of-wilms-tumor-a-nationwide-cohort-study-with-sibling-controls
#39
JOURNAL ARTICLE
Stine Høgsholt, Peter Haubjerg Asdahl, Catherine Rechnitzer, Jeanette Falck Winther, Henrik Birn, Henrik Hasle
BACKGROUND: Survival after Wilms tumor has significantly increased and focus on late effects has become increasingly important. However, knowledge about long-term renal function in survivors of Wilms tumor is missing. Our aim was to investigate evidence of kidney disease in 20- or more-year survivors of Wilms tumor in a clinical setting, with siblings as comparisons. METHODS: In this cross-sectional study, we established a cohort of Danish 20-plus-year survivors of Wilms tumor and siblings as controls...
July 16, 2022: Cancer Medicine
https://read.qxmd.com/read/35814456/an-integrated-analysis-of-clinical-genomic-and-imaging-features-reveals-predictors-of-neurocognitive-outcomes-in-a-longitudinal-cohort-of-pediatric-cancer-survivors-enriched-with-cns-tumors-rad-art-pro
#40
JOURNAL ARTICLE
Cassie Kline, Schuyler Stoller, Lennox Byer, David Samuel, Janine M Lupo, Melanie A Morrison, Andreas M Rauschecker, Pierre Nedelec, Walter Faig, Dena B Dubal, Heather J Fullerton, Sabine Mueller
Background: Neurocognitive deficits in pediatric cancer survivors occur frequently; however, individual outcomes are unpredictable. We investigate clinical, genetic, and imaging predictors of neurocognition in pediatric cancer survivors, with a focus on survivors of central nervous system (CNS) tumors exposed to radiation. Methods: One hundred eighteen patients with benign or malignant cancers (median diagnosis age: 7; 32% embryonal CNS tumors) were selected from an existing multi-institutional cohort (RadART Pro) if they had: 1) neurocognitive evaluation; 2) available DNA; 3) standard imaging...
2022: Frontiers in Oncology
keyword
keyword
86023
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.